ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
62,736.84
2.53%
S&P 500
5,214.08
0.51%
Dow Jones
39,387.76
0.85%
US Dollar vs Yen
155.312
-0.07%
Brent Oil
83.95
0.47%
Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Recursion Pharmaceuticals Inc (RXRX)

  7. Recursion Pharmaceuticals Inc (RXRX) ニュース

RXRX

Recursion Pharmaceuticals (RXRX)

Recursion Pharmaceuticals Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:RXRX
日付受信時刻ニュースソース見出しコード企業名
2024/05/1005 : 11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/05/1005 : 01GlobeNewswire Inc.Recursion Provides Business Updates and Reports First Quarter 2024 Financial ResultsNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/05/0221 : 00GlobeNewswire Inc.Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9NASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/05/0121 : 01GlobeNewswire Inc.Recursion to Participate in Upcoming Investor ConferencesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/04/3021 : 00GlobeNewswire Inc.Altitude Lab Secures Small Business Administration Growth Fund Accelerator Grant to Launch Horizon, a Commercialization Partnering ProgramNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/04/1621 : 00GlobeNewswire Inc.Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial OfficerNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/04/0221 : 00GlobeNewswire Inc.Recursion to Participate in Upcoming Investor ConferenceNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/03/2621 : 00GlobeNewswire Inc.Recursion Publishes Annual Environmental, Social and Governance ReportNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/03/1117 : 00GlobeNewswire Inc.Recursion Announces Plans to Open New Office in LondonNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/03/0909 : 08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/03/0808 : 53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/03/0707 : 39Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/03/0706 : 59Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/03/0606 : 18Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/03/0204 : 58GlobeNewswire Inc.Recursion Hosts Second Annual Rare Disease Day Events for Utah’s Rare Disease CommunityNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/03/0121 : 59GlobeNewswire Inc.Recursion to Participate in Upcoming Investor ConferencesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/02/2922 : 25Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/02/2806 : 05GlobeNewswire Inc.Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial ResultsNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/02/2409 : 22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/02/2308 : 13Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/02/2207 : 37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/02/2106 : 29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/02/2021 : 59GlobeNewswire Inc.Recursion to Host Public L(earnings) Call on February 27NASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/02/1709 : 59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/02/1709 : 58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/02/1709 : 57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/02/1608 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/02/1506 : 50Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/02/1409 : 03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/02/1409 : 01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:RXRX

最近閲覧した銘柄

FX
USDGBP
US Dollar vs Sterling
CCOM
US100
US Tech 100
NYSE
MRK
Merck
NYSE
JPM
JP Morgan Chase
AMEX
XLV
Health Care Select Sector
NASDAQ
GOOGL
Alphabet
SPI
SP500
S&P 500
USOTC
DTEGY
Deutsche Telekom (QX)
USOTC
BASFY
BASF (QX)
CCOM
SILVER
SILVER
NYSE
XOM
Exxon Mobil
AMEX
XLE
Energy Select Sector SPDR
NASDAQ
MSFT
Microsoft
NASDAQ
TSLA
Tesla
FX
USDEUR
US Dollar vs Euro
NYSE
AXP
American Express
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有